The new measures come amid a turbulent period for the company, which specialises in artificial intelligence-powered drug discovery and development, with a change of CEO and a series of board changes instigated by founder and major shareholder Ken Mulvany, who has been unhappy with the direction it has taken.
BenevolentAI Provides an Update on Its Business Priorities
BenevolentAI Announces Positive Topline Data from the Phase Ia Study of BEN-8744
BenevolentAI: Publication of 2023 Annual Report and 2024 AGM Notice
BenevolentAI Appoints New Chief Technology Officer
BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2023
BenevolentAI: Notice of Preliminary Results
Last year was rocky for a number of the first AI-based biotechs that entered the clinic, including BenevolentAI. But a new year spells new hope and the company has a fresh captain to try and steady the ship.
BenevolentAI to present at 42nd Annual J.P. Morgan Healthcare Conference
BenevolentAI: Shareholder Letter December 2023